Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition

BACKGROUND: Prostate cancer responds poorly to current immunotherapies. Epigenetic therapies such as BET Bromodomain inhibition can change the transcriptome of tumor cells, possibly making them more immunogenic and thus susceptible to immune targeting. METHODS: We characterized the effects of BET br...

Descripción completa

Detalles Bibliográficos
Autores principales: Mao, Wendy, Ghasemzadeh, Ali, Freeman, Zachary T., Obradovic, Aleksandar, Chaimowitz, Matthew G., Nirschl, Thomas R., McKiernan, Emily, Yegnasubramanian, Srinivasan, Drake, Charles G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6814994/
https://www.ncbi.nlm.nih.gov/pubmed/31653272
http://dx.doi.org/10.1186/s40425-019-0758-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6814994/
https://www.ncbi.nlm.nih.gov/pubmed/31653272
http://dx.doi.org/10.1186/s40425-019-0758-y

Ejemplares similares